BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4 th at 9:20 AM EDT. For more information and a link to the webcast , visit the... Read More

Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2027 BERKELEY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for... Read More

BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13 th at 2:35 PM PDT. For more information and a link to the webcast , visit the... Read More

Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in H2 2025 CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design CB-011... Read More

CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 Advancing four clinical programs for hematologic malignancies and autoimmune diseases $249.4 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2026 BERKELEY, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading... Read More

BERKELEY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference February 25, 2025, fireside chat at 11:30 AM ET Webcast... Read More

CB-010 GALLOP Phase 1 trial initiated in lupus CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 Sri Ryali appointed chief financial officer Caribou to present at 43 r d Annual J.P. Morgan Healthcare Conference on Thursday, January 16, at 10:30 am PST BERKELEY, Calif.,... Read More

BERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 am PST. For more information and... Read More

BERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as chief financial officer, effective immediately. Mr. Ryali brings 20 years of finance and commercial experience... Read More

BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences: Citi's 2024 Global Healthcare Conference , Miami, FL December 3, 2024, panel at 2:30 PM EST Panel title: Cell... Read More

Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 Enrolling patients with LBCL (2L and after prior CD19-targeted therapies) with HLA matching strategy in CB-010 ANTLER Phase 1 trial; next data report planned for H1 2025 Continuing dose escalation portion of the CB-011 CaMMouflage Phase 1 trial in r/r MM with higher lymphodepletion... Read More

BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract has been accepted for a poster presentation at the American College of Rheumatology (ACR) Convergence 2024, which will be held November 14-19, 2024 in Washington, DC. The poster will highlight the preclinical data and key elements... Read More

Fast Track designation is designed to expedite clinical development and regulatory review timelines Additional FDA designation for CB-010 following earlier RMAT and Fast Track designations in B-NHL CB-010 GALLOP Phase 1 trial in patients with LN and ERL is on track to initiate by YE 2024 CB-012 AMpLify Phase 1 trial advancing in dose escalation BERKELEY, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc.... Read More

BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company leadership will participate in the following event and investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference , New York, NY September 4, 2024 2024 Wells Fargo Healthcare Conference , Boston, MA September 5, 2024... Read More

Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc . (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15... Read More

Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; clinical data reports planned for 2024 and H1 2025 Enrolling 2L LBCL and prior CD19 relapsed LBCL patients based on CB-010 ANTLER Phase 1 data presented at 2024 ASCO Annual Meeting; data to be presented H1 2025 $311.8 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into H2... Read More

Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board . Dr. Laufer is a leading rheumatologist known for her extensive... Read More

CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA... Read More

BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following event and investor conferences: • Caribou’s webcast of KOL discussion from 2024 American Society of Clinical Oncology (ASCO) Annual Meeting June 2, 2024, CB-010 ANTLER Phase 1 clinical trial data in... Read More

Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases;... Read More

BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: 2024 RBC Capital Markets Global Healthcare Conference , New York, NY May 14, 2024, fireside chat at 3:35 pm EDT Webcast BofA Securities 2024 Health Care Conference , Las Vegas,... Read More

BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois. The ANTLER poster will provide initial dose... Read More

BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on the efficient use of Cas12a chRDNA genome-editing technology for in vivo hepatic gene disruption has been accepted for an oral presentation at the 27 th annual meeting of the American Society of Gene and Cell Therapy (ASGCT),... Read More

FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases Advancing ANTLER Phase 1 trial for 2L LBCL; initial dose expansion data to be shared at a medical congress... Read More

30 th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 1 st patient dosed in CB-012 AMpLify Phase 1 trial for patients with r/r AML $372.4 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into Q1 2026 BERKELEY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU),... Read More

BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc . (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclinical data from CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML), will be presented as a poster at the upcoming American Association for Cancer... Read More

BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: Citi's 2024 Virtual Oncology Leadership Summit February 21, 2024, fireside chat at 12:00 pm EST Leerink Global Biopharma Conference March 12, 2024, fireside chat at 1:40 pm EDT... Read More

Tim Kelly to lead Caribou’s technical operations strategy and execution CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate pivotal Phase 3 trial in 2L LBCL by YE 2024 CB-011 CaMMouflage Phase 1 trial enrolling patients at dose level 3; initial dose escalation... Read More

Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 Caribou plans to initiate Phase 3 pivotal trial by YE 2024 BERKELEY, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a... Read More

CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024 CB-011 CaMMouflage Phase 1 trial enrollment ongoing in r/r MM patients CB-012 AMpLify Phase 1 trial site activation underway following recent IND clearance; expect to initiate enrollment by mid-2024 in r/r AML patients $396.7 million in... Read More

Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory board . With four decades of experience, Dr. Jagannath is a renowned expert in bone marrow... Read More

BERKELEY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: Truist Securities BioPharma Symposium November 9, 2023 Jefferies London Healthcare Conference November 15, 2023, corporate presentation at 12:30 pm GMT 6 th Annual Evercore ISI... Read More

AMpLify Phase 1 clinical trial to initiate patient enrollment by mid-2024 CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption and immune cloaking to enter the clinic BERKELEY, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR... Read More

BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Reigin Zawadzki to the newly created position of chief people officer. Ms. Zawadzki brings over 20 years of experience leading human resources in the biotechnology industry. She will lead Caribou’s people strategy and report... Read More

BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: Citi 18 th Annual BioPharma Conference, Boston, MA September 6, 2023 Wells Fargo Healthcare Conference, Boston, MA September 7, 2023, 8:00 am EDT Morgan Stanley 21 st Annual... Read More

CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 CB-011 CaMMouflage Phase 1 trial enrollment continues in r/r MM CB-012 IND application submission for r/r AML planned for H2 2023 Received $25.0 million equity investment from Pfizer Closed upsized public offering including full exercise of underwriters’ option to... Read More

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 19,230,769 shares of its common stock at a public offering price of $6.50 per share. All of the common stock to be sold in the offering will be offered by Caribou. The gross proceeds to... Read More

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has commenced an underwritten public offering of $100 million of shares of its common stock. Caribou intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock at the public... Read More

CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010; 24 months is the longest CR maintained to date LBCL patient subgroup had... Read More

Pfizer purchases $25 million of Caribou common shares Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development, has joined Caribou’s Scientific Advisory Board BERKELEY, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Pfizer Inc. (NYSE:... Read More

BERKELEY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to present at the following investor conferences during the month of June: Jefferies Healthcare Conference, New York, NY June 7, 2023, 3:00 pm EDT Webcast... Read More

CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients at dose level 1 CB-012 IND application for r/r AML planned for H2 2023 $291.0 million in cash, cash equivalents, and marketable securities as of March 31, 2023; cash runway to fund the current operating plan into 2025 BERKELEY, Calif., May... Read More

Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Stephen J. Schuster, MD, to its scientific advisory board (SAB). Dr. Schuster is an expert in treating patients with lymphoma and... Read More

BERKELEY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to present at the following investor conferences during the month of May: BofA Securities 2023 Healthcare Conference, Las Vegas, NV May 10, 2023, 3:00 pm PDT... Read More

CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models CB-012 IND-enabling studies ongoing; IND submission in r/r AML planned for H2 2023 BERKELEY, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today presents a poster of preclinical data... Read More

CaMMouflage Phase 1 trial for CB-011 enrolling patients with r/r MM at dose level 1 BERKELEY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-011, which is being developed for relapsed or refractory multiple... Read More

CB-010 is the first allogeneic CAR-T cell therapy, to Caribou’s knowledge, to be evaluated clinically in second-line LBCL patients Next ANTLER update planned for H2 2023 BERKELEY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced initiation of the dose expansion portion of the CB-010 ANTLER Phase 1... Read More

CB-011 is designed to improve antitumor activity by cloaking the allogeneic CAR-T cells from immune-mediated rejection CB-011 is Caribou’s second program to enter the clinic from its off-the-shelf CAR-T cell therapy platform BERKELEY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the first patient... Read More

CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 CB-012 IND-enabling studies initiated; IND submission in r/r AML planned for H2 2023 $317.0 million in cash, cash equivalents, and marketable securities as of December 31, 2022; cash runway to fund the current operating plan into 2025 BERKELEY, Calif., March 09, 2023... Read More

BERKELEY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to participate in a fireside chat at the virtual Oppenheimer 33 rd Annual Healthcare Conference on March 15, 2023, at 10:40 am EDT. Register for the live... Read More

BERKELEY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, is scheduled to participate in the following investor conferences: Guggenheim Oncology Conference 2023 , New York City February 9, 2023, 10:45 am EST Webcast SVB... Read More

BERKELEY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, is scheduled to present a corporate update at the 41 st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 11:15 am PST. A live webcast of the... Read More